ClinicalTrials.gg
CompletedNCT02104674Updated Jul 17, 2026Results posted

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

A Phase 3 interventional study of Lebrikizumab and Montelukast in Asthma, sponsored by Hoffmann-La Roche. Completed at 82 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
4th of 12
313 · median 224
Started
2014
with 2 others
Phase 3
5 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA) therapy alone. Patients will be randomized in a 1:1:1 ratio to receive either blinded lebrikizumab or placebo treatment by subcutaneous (SC) injection (every 4 weeks for a total of 3 doses) or open-label treatment with Singulair (Montelukast; 10 mg daily). Time on study treatment will last 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old at study start
  • Asthma diagnosis for >/= 12 months prior to study start
  • Bronchodilator response at screening
  • Pre-bronchodilator of 60% - 85% predicted at both screening visits 2 and 3
  • No other lung disease as confirmed by chest X-ray or computed tomography (CT) scan
  • Stable and symptomatic asthma during the screening period
  • Use of effective , as defined by the protocol, until 24 weeks after the last dose

Exclusion criteria

Exclusion Criteria:

  • Maintenance of therapy, defined as daily or alternate-day oral corticosteroid maintenance therapy within 3 months prior to study start
  • Treatment with systemic or inhaled corticosteroids within 4 weeks prior to study start or during the screening period for any reason, including an acute exacerbation event
  • Treatment with a leukotriene receptor antagonist (LTRA), long-acting beta-agonist (LABA) long-acting muscarinic antagonist (LAMA), zileuton, roflumilast, or theophylline within 2 weeks prior to study start
  • Documented prior treatment failure with Montelukast
  • Treatment with intra-articular corticosteroids within 4 weeks prior to study start or during the screening period or anticipated need for intra articular corticosteroids during the course of the study
  • Any infection requiring hospital, IV or IM antibiotic treatment or any respiratory infection within 4 weeks of study start. Any infection requiring oral antibiotic treatment within 2 weeks of study start, or any parasitic infection within 6 months of study start
  • abnormality found during screening or clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study, or impact the study assessments
  • History of interstitial lung disease, (COPD), or other clinically significant lung disease other than asthma
  • History of alcohol or drug abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator
  • Current or history of smoking (> 10 pack-years), or unwillingness to abstain from smoking for the duration of the study
  • Past and/or current use of any anti-IL-13 or anti- IL4/IL-13 therapy, including lebrikizumab
  • Use of a licensed or monoclonal antibody other than anti IL-13 or anti-IL-4/IL-13, including, but not limited to, omalizumab, anti-IL-5, or anti IL-17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Use of a systemic immunomodulatory or therapy within 3 months or 5 drug half-lives prior to study start or during screening
  • Use of other investigational therapy within 4 weeks or 5 drug half-lives prior to study start (whichever is longer) or during screening
  • Initiation of or change in allergen immunotherapy within 3 months prior to study start or during screening
  • Receipt of a within 4 weeks prior to study start of during screening
  • Pregnancy or breast feeding
  • > 38 kg/m2
  • Body weight \< 40 kg
  • History of bronchial thermoplasty
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    Lebrikizumab

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Other: Placebo

  • Active comparator
    Montelukast

    Drug: Montelukast

Interventions

  • Lebrikizumab 125 mg subcutaneous (SC) injection given on Days 1, 29, and 57

    Also known as: RO5490255

  • 10 mg tablet given orally once daily for 12 weeks, according to the approved label.

    Also known as: Singulair

  • OtherPlacebo

    Lebrikizumab-matched placebo SC injection given on Days 1, 29, and 57

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to the primary outcome measure, FEV1. Two mixed-effect models of repeated measures (MMRM) were used to estimate the absolute change from baseline values: one for the lebrikizumab vs. placebo primary comparison and the second for the montelukast vs. placebo sensitivity comparison.

    Time frame: Baseline through Week 12

Secondary outcomes

  1. Lebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12

    Participants could only receive SABA therapy for asthma treatment as asthma reliever medication (\<10 puffs daily). SABA use was recorded in the eDiary. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.

    Time frame: Baseline through Week 12

  2. Lebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 12

    The AQLQ\[S\] was used to assess the participant's asthma-specific health-related quality of life. The 32-item questionnaire contains four domains: activity limitations, symptoms, emotional function, and environmental stimuli. The AQLQ\[S\] has a recall specification of 2 weeks. Participants were asked to think about how they had been during the previous 2 weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all; 1 = severely impaired). An increase in the AQLQ score indicates a better quality of life. The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains. A mixed-effect model of repeated measures (MMRM) was used to estimate the change from baseline values.

    Time frame: Baseline through Week 12

  3. Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels at Week 12

    Time frame: Baseline, Week 12

  4. Montelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 12

    PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to this secondary outcome measure of PEF. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the sensitivity comparison between montelukast (open-label, active comparator) and placebo study arms.

    Time frame: Baseline through Week 12

  5. Lebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 12

    Peak expiratory flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.

    Time frame: Baseline through Week 12

  6. Lebrikizumab vs. Placebo: Number of Participants With Treatment Failure

    Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. The hazard ratio from the Cox Proportional Hazards model compared the risk of treatment failure for the lebrikizumab-treated and placebo participants.

    Time frame: Baseline up to Week 12

  7. Lebrikizumab vs. Placebo: Time to Treatment Failure

    Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. Time to treatment failure was estimated using Kaplan-Meier method.

    Time frame: Basleine up to Week 12

  8. Change From Baseline in Blood Eosinophil Count at Week 12

    Time frame: Baseline, Week 12

  9. Change From Baseline in Serum Periostin at Week 12

    Time frame: Baseline, Week 12

  10. Change From Baseline in Total Immunoglobulin E (IgE) Levels at Week 12

    Time frame: Baseline, Week 12

  11. Change From Baseline in C-C Motif Chemokine Ligand 13 (CCL-13) Levels at Week 12

    Time frame: Baseline, Week 12

  12. Change From Baseline in CCL-17 Levels at Week 12

    Time frame: Baseline, Week 12

  13. Maximum Serum Lebrikizumab Concentration (Cmax) After the First Dose

    According to the protocol and statistical analysis plan, a single PK sample was collected per participant after the first dose at the expected time of the maximum serum lebrikizumab concentration.

    Time frame: Predose on Day 0 and post-Day 1 dose on Day 7

  14. Time to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax)

    According to the protocol and statistical analysis plan, the Tmax, Week1 (first dose) value was estimated on the basis of a single pharmacokinetic (PK) timepoint per participant after the first dose, which was taken at the expected time of the maximum serum lebrikizumab concentration.

    Time frame: Post-Day 1 dose on Day 7

  15. Elimination Half-Life (t1/2) of Lebrikizumab

    According to the protocol and statistical analysis plan, the t1/2 was estimated based on the seven total PK samples collected per participant.

    Time frame: Predose on Days 0, 28, and 56, and on Days 7, 84, 112, and 140

  16. Predose Serum Lebrikizumab Concentration (Cmin) at Week 4

    Time frame: Predose on Day 28 (Week 4)

  17. Serum Lebrikizumab Concentration at Week 12

    Time frame: On Day 84 (Week 12)

07

Results

Posted Jul 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneDouble-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: Montelukast
Started105106102
Received at least 1 dose of study drug104105101
Completed989891
Not completed7811
Withdrew: Withdrawal by subject547
Withdrew: Other110
Withdrew: Adverse event111
Withdrew: Lost to follow-up012
Withdrew: Lack of efficacy011

Outcome measures

SecondaryLebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12

Participants could only receive SABA therapy for asthma treatment as asthma reliever medication (\<10 puffs daily). SABA use was recorded in the eDiary. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Puffs/day
Lebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12
Puffs/dayDouble-Blind: LebrikizumabDouble-Blind: Placebo
Lebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12-0.51 ± 0.108-0.55 ± 0.108
Statistical analysis
  • Double-Blind: Lebrikizumab vs Double-Blind: Placebo · Mixed Model of Repeated Measures (MMRM) · p = 0.7835 · Mean difference (final values): 0.04 · 95% CI -0.24 to 0.32
SecondaryLebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 12

The AQLQ\[S\] was used to assess the participant's asthma-specific health-related quality of life. The 32-item questionnaire contains four domains: activity limitations, symptoms, emotional function, and environmental stimuli. The AQLQ\[S\] has a recall specification of 2 weeks. Participants were asked to think about how they had been during the previous 2 weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all; 1 = severely impaired). An increase in the AQLQ score indicates a better quality of life. The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains. A mixed-effect model of repeated measures (MMRM) was used to estimate the change from baseline values.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Units on scale
Lebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 12
Units on scaleDouble-Blind: LebrikizumabDouble-Blind: Placebo
Lebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 120.62 ± 0.0880.68 ± 0.086
Statistical analysis
  • Double-Blind: Lebrikizumab vs Double-Blind: Placebo · Mixed Model of Repeated Measures (MMRM) · p = 0.6185 · Mean difference (final values): -0.06 · 95% CI -0.29 to 0.17
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · parts per billion (ppb)
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels at Week 12
parts per billion (ppb)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: Montelukast
Baseline (n= 104, 103, 103)52.85 ± 44.9850.66 ± 44.4965.89 ± 67.81
Change at Week 12 (n= 84, 86, 92)-31.85 ± 36.13-10.86 ± 28.41-13.21 ± 33.28
SecondaryMontelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 12

PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to this secondary outcome measure of PEF. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the sensitivity comparison between montelukast (open-label, active comparator) and placebo study arms.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Liters/minute
Montelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 12
Liters/minuteOpen-Label: MontelukastDouble-Blind: Placebo
Montelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 125.92 ± 5.9734.69 ± 5.872
Statistical analysis
  • Open-Label: Montelukast vs Double-Blind: Placebo · Mixed Model of Repeated Measures (MMRM) · p = 0.8777 · Mean difference (final values): 1.23 · 95% CI -14.57 to 17.04Montelukast minus Placebo
SecondaryLebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 12

Peak expiratory flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Liters/minute
Lebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 12
Liters/minuteDouble-Blind: LebrikizumabDouble-Blind: Placebo
Lebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 121.63 ± 5.5515.25 ± 5.565
Statistical analysis
  • Double-Blind: Lebrikizumab vs Double-Blind: Placebo · Mixed Model of Repeated Measures (MMRM) · p = 0.6315 · Mean difference (final values): -3.61 · 95% CI -18.46 to 11.23Lebrikizumab minus Placebo
SecondaryLebrikizumab vs. Placebo: Number of Participants With Treatment Failure

Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. The hazard ratio from the Cox Proportional Hazards model compared the risk of treatment failure for the lebrikizumab-treated and placebo participants.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Lebrikizumab vs. Placebo: Number of Participants With Treatment Failure
ParticipantsDouble-Blind: LebrikizumabDouble-Blind: Placebo
Lebrikizumab vs. Placebo: Number of Participants With Treatment Failure911
Statistical analysis
  • Double-Blind: Lebrikizumab vs Double-Blind: Placebo · Regression, Cox · p = 0.8839 · Hazard ratio (hr): 1.06 · 95% CI 0.47 to 2.42
SecondaryLebrikizumab vs. Placebo: Time to Treatment Failure

Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. Time to treatment failure was estimated using Kaplan-Meier method.

Time frame:
Basleine up to Week 12
Reported as:
Median · Days
Lebrikizumab vs. Placebo: Time to Treatment Failure
DaysDouble-Blind: LebrikizumabDouble-Blind: Placebo
Lebrikizumab vs. Placebo: Time to Treatment FailureNA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Blood Eosinophil Count at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · cells/microliter (cells/mcL)
Change From Baseline in Blood Eosinophil Count at Week 12
cells/microliter (cells/mcL)Double-Blind: LebrikizumabOpen-Label: MontelukastDouble-Blind: Placebo
Baseline (n= 104, 103, 103)230.10 ± 149.90262.04 ± 169.84233.30 ± 152.61
Change at Week 12 (n= 84, 90, 91)55.12 ± 215.83-32.67 ± 165.9433.52 ± 173.87
SecondaryChange From Baseline in Serum Periostin at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · Nanogram/milliliter (ng/mL)
Change From Baseline in Serum Periostin at Week 12
Nanogram/milliliter (ng/mL)Double-Blind: LebrikizumabOpen-Label: MontelukastDouble-Blind: Placebo
Baseline (n= 104, 103, 103)53.85 ± 16.7154.60 ± 16.1855.37 ± 19.15
Change at Week 12 (n= 88, 90, 91)-3.92 ± 9.68-1.30 ± 7.720.33 ± 8.13
SecondaryChange From Baseline in Total Immunoglobulin E (IgE) Levels at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · Microgram (Mcg)/mL
Change From Baseline in Total Immunoglobulin E (IgE) Levels at Week 12
Microgram (Mcg)/mLDouble-Blind: LebrikizumabOpen-Label: MontelukastDouble-Blind: Placebo
Baseline (n= 103, 103, 102)994.46 ± 2032.99565.42 ± 1051.63868.28 ± 1422.97
Change at Week 12 (n= 86, 89, 89)-200.71 ± 643.4626.10 ± 408.43-80.28 ± 582.12
SecondaryChange From Baseline in C-C Motif Chemokine Ligand 13 (CCL-13) Levels at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · Picogram/mL (pg/mL)
Change From Baseline in C-C Motif Chemokine Ligand 13 (CCL-13) Levels at Week 12
Picogram/mL (pg/mL)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: Montelukast
Baseline (n= 104, 102, 103)192.79 ± 87.77206.19 ± 91.04201.34 ± 81.13
Change at Week 12 (n= 88, 90, 90)-35.79 ± 57.724.36 ± 72.000.19 ± 51.31
SecondaryChange From Baseline in CCL-17 Levels at Week 12
Time frame:
Baseline, Week 12
Reported as:
Mean · pg/mL
Change From Baseline in CCL-17 Levels at Week 12
pg/mLDouble-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: Montelukast
Baseline (n= 104, 102, 103)506.49 ± 1476.14365.48 ± 206.23326.09 ± 189.33
Change at Week 12 (n= 87, 90, 90)-133.93 ± 764.1423.93 ± 169.015.79 ± 134.93
SecondaryMaximum Serum Lebrikizumab Concentration (Cmax) After the First Dose

According to the protocol and statistical analysis plan, a single PK sample was collected per participant after the first dose at the expected time of the maximum serum lebrikizumab concentration.

Time frame:
Predose on Day 0 and post-Day 1 dose on Day 7
Reported as:
Mean · Mcg/mL
Maximum Serum Lebrikizumab Concentration (Cmax) After the First Dose
Mcg/mLDouble-Blind: Lebrikizumab
Maximum Serum Lebrikizumab Concentration (Cmax) After the First Dose14.9 ± 5.91
SecondaryTime to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax)

According to the protocol and statistical analysis plan, the Tmax, Week1 (first dose) value was estimated on the basis of a single pharmacokinetic (PK) timepoint per participant after the first dose, which was taken at the expected time of the maximum serum lebrikizumab concentration.

Time frame:
Post-Day 1 dose on Day 7
Reported as:
Mean · Days
Time to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax)
DaysDouble-Blind: Lebrikizumab
Time to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax)7.04 ± 1.17
SecondaryElimination Half-Life (t1/2) of Lebrikizumab

According to the protocol and statistical analysis plan, the t1/2 was estimated based on the seven total PK samples collected per participant.

Time frame:
Predose on Days 0, 28, and 56, and on Days 7, 84, 112, and 140
Reported as:
Mean · Days
Elimination Half-Life (t1/2) of Lebrikizumab
DaysDouble-Blind: Lebrikizumab
Elimination Half-Life (t1/2) of Lebrikizumab23.7 ± 7.24
SecondaryPredose Serum Lebrikizumab Concentration (Cmin) at Week 4
Time frame:
Predose on Day 28 (Week 4)
Reported as:
Mean · Mcg/mL
Predose Serum Lebrikizumab Concentration (Cmin) at Week 4
Mcg/mLDouble-Blind: Lebrikizumab
Predose Serum Lebrikizumab Concentration (Cmin) at Week 49.58 ± 4.12
SecondarySerum Lebrikizumab Concentration at Week 12
Time frame:
On Day 84 (Week 12)
Reported as:
Mean · Mcg/mL
Serum Lebrikizumab Concentration at Week 12
Mcg/mLDouble-Blind: Lebrikizumab
Serum Lebrikizumab Concentration at Week 1218.1 ± 6.46
PrimaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to the primary outcome measure, FEV1. Two mixed-effect models of repeated measures (MMRM) were used to estimate the absolute change from baseline values: one for the lebrikizumab vs. placebo primary comparison and the second for the montelukast vs. placebo sensitivity comparison.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
LitersDouble-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: Montelukast
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 120.15 ± 0.0330.07 ± 0.0320.05 ± 0.032
Statistical analysis
  • Double-Blind: Lebrikizumab vs Double-Blind: Placebo · MMRM · p = 0.06 (Mixed model of repeated measures (MMRM) was used to model the absolute change from baseline.) · Mean difference (final values): 0.08 · 95% CI 0 to 0.17
  • Double-Blind: Placebo vs Open-Label: Montelukast · MMRM · p = 0.6954 (MMRM was used to model the absolute change from baseline.) · Mean difference (final values): -0.02 · 95% CI -0.1 to 0.07

Adverse events

Collected over Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lebrikizumab-Safety0/104 (0%)2/104 (1.9%)25/104 (24%)
Placebo-Safety0/103 (0%)1/103 (1%)24/103 (23.3%)
Montelukast-Safety0/103 (0%)0/103 (0%)33/103 (32%)
Most frequent serious events
Most frequent serious events
EventLebrikizumab-SafetyPlacebo-SafetyMontelukast-Safety
Subdural haematomaInjury, poisoning and procedural complications0/1041/1030/103
Cerebrospinal fluid leakageNervous system disorders0/1041/1030/103
Anaphylactic reactionImmune system disorders1/1040/1030/103
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1040/1030/103
Most frequent other events
Most frequent other events
EventLebrikizumab-SafetyPlacebo-SafetyMontelukast-Safety
AsthmaRespiratory, thoracic and mediastinal disorders6/10412/10312/103
NasopharyngitisInfections and infestations9/1045/10311/103
Upper respiratory tract infectionInfections and infestations9/1045/1038/103
HeadacheNervous system disorders3/1046/1035/103

Baseline characteristics

mITT Population: all participants who received at least one dose of study treatment, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
Mean42.9 ± 13.844.7 ± 14.044.2 ± 13.343.9 ± 13.7
Age, Customized
Age, Customized(Participants)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
18 to <30 years22191758
30 to <50 years474448139
50 to <65 years28333293
≥65 years79420
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
Female636661190
Male413940120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
Hispanic or Latino10111031
Not Hispanic or Latino939491278
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
American Indian or Alaska Native1012
Asian24511
Native Hawaiian or Other Pacific Islander0000
Black or African American13201043
White888184253
More than one race0011
Unknown or Not Reported0000
Biomarker Classification According to Periostin and Eosinophil Levels
Biomarker Classification According to Periostin and Eosinophil Levels(Participants)Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
Periostin ≥50 ng/ml and Eosinophils ≥300 cells/ul21232165
Periostin ≥50 ng/ml and Eosinophils <300 cells/ul374134112
Periostin <50 ng/ml and Eosinophils ≥300 cells/ul911626
Periostin <50 ng/ml and Eosinophils <300 cells/ul373040107
Pre-bronchodilator FEV1
Pre-bronchodilator FEV1(Liters (L))Double-Blind: LebrikizumabDouble-Blind: PlaceboOpen-Label: MontelukastTotal
Mean2.39 ± 0.592.31 ± 0.632.38 ± 0.572.36 ± 0.60
08

Study locations

82 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35209, United States
  • Allergy & Asthma Immunology Associates
    Scottsdale, Arizona 85251, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • CA Allergy & Asthma Med Grp; Medical Group, Inc.
    Los Angeles, California 90025, United States
  • Southern California Institute For Respiratory
    Los Angeles, California 90048, United States
  • North Bay Clinical Trials
    Napa, California 94558, United States
  • Advances in Medicine
    Rancho Mirage, California 92270, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • Integrated Research Group Inc
    Riverside, California 92506, United States
  • Storms Clinical Research; Institute
    Colorado Springs, Colorado 80907, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Florida Pulmonary Research Institute, LLC
    Winter Park, Florida 32789, United States
  • In-Quest Medical Research, LLC
    Duluth, Georgia 30096, United States
  • Sneeze, Wheeze, & Itch Associates
    Normal, Illinois 61761, United States
  • Asthma & Allergy Center of Chicago, S.C.
    River Forest, Illinois 60305, United States
  • Family Allergy & Asthma
    Louisville, Kentucky 40223, United States
  • Midwest Clinical Research LLC
    St Louis, Missouri 63141, United States
  • The Clinical Research Ctr
    St Louis, Missouri 63141, United States
  • Asthma & Allergy Center, P.C.
    Papillion, Nebraska 68046, United States
  • Advanced Research Institute
    Reno, Nevada 89511, United States
  • Atlantic Research Center, LLC
    Ocean City, New Jersey 07712, United States
  • Urban Health Plan, Inc.
    The Bronx, New York 10459, United States
  • Allergy, Asthma & Clinical Research Center
    Oklahoma City, Oklahoma 73120, United States
  • Clinical Research Inst. of Southern Oregon, Pc
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center LLC - CRN
    Portland, Oregon 97202, United States
  • Mountainview Clinical Research
    Greer, South Carolina 29651, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Allergy Asthma Research Assoc
    Dallas, Texas 75231, United States
  • Pharmaceutical Research & Consulting, Inc.
    Dallas, Texas 75231, United States
  • Texas Institute of chest and Sleep Disorder
    Houston, Texas 77034, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Quality Assurance Research Center
    San Antonio, Texas 78207, United States
  • Bandera Family Health Care
    San Antonio, Texas 78249, United States
  • South Texas Allergy and Asthma Medical Professionals
    San Antonio, Texas 78251, United States
  • Allergy & Asthma Center
    Waco, Texas 76712, United States
  • O & O Alpan, LLC
    Fairfax, Virginia 22030, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23220, United States
  • Allergy Asthma & Sinus Center
    Greenfield, Wisconsin 53228, United States
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Ufsc - Nupaiva
    Florianópolis, Santa Catarina 88040-970, Brazil
  • Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
    Santo André, São Paulo 09060-650, Brazil
  • Pesquisare Saúde Sociedade Simples
    Santo André, São Paulo 09080-000, Brazil
  • SHATPD ? Gabrovo EOOD; Department of pneumology
    Gabrovo, 5300, Bulgaria
  • MHAT "Sv. Ivan Rilski" ? Razgrad AD; Department of pnemology and phthisiatry
    Razgrad, 7200, Bulgaria
  • SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd.
    Rousse, 7002, Bulgaria
  • Medical Center Excelsior OOD
    Sofia, 1000, Bulgaria
  • Medical Center Researchexpert OOD
    Varna, 9000, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, 5000, Bulgaria
  • Aggarwal and Associates
    Brampton, Ontario L6T 0G1, Canada
  • Dr. Anil K. Gupta Medicine Professional Corporation
    Toronto, Ontario M9V 4B4, Canada
  • MediTrial s.r.o.
    Jind?ich?v Hradec, 377 01, Czechia
  • Pneumo - KV; Ordinace pneumologie a diagnostiky plicních funkcí
    Karlovy Vary ? Stará Role, 360 17, Czechia
  • Ordinace pro tuberkulozu a respiracni nemoci
    Strakonice, 38601, Czechia
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • Southern Clinical Trials, Ltd
    Beckenham, 8024, New Zealand
  • Uniwersytecki Szpital Kliniczny w Bialymstoku Klinika Alergologii i Chorob Wewnetrznych
    Bialystok, 15-276, Poland
  • Grazyna Pulka Specjalistyczny Osrodek ALL-MED
    Krakow, 31-023, Poland
  • GRA?YNA JASIENIAK-PINIS ATOPIA Niepubliczny Zak?ad Opieki Zdrowotnej Poradnie Specjalistyczne
    Krakow, 31-159, Poland
  • Specjalistyczny Niepubliczny Zespol Opieki Zdrowotnej; Alergologia Plus Osrodek Diagnostyki.
    Poznan, 60-693, Poland
  • NZOZ Alergo-Med. Specjalistyczna Przychodnia Lekarska; Poradnia Alergologiczna
    Poznan, 60-823, Poland
  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o
    Tarnów, 33-100, Poland
  • NZOZ ALL-MED Specjalistyczna Opieka Medyczna
    Wroclaw, 53-201, Poland
  • Compartiment Pneumologie; Fundatia Dr. Victor Babes
    Bucharest, 030303, Romania
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes; Sectia Pneumologie II
    Craiova, 200446, Romania
  • Spitalul Clinic de Pneumoftiziologie Iasi; Sectia Clinica I Pneumoftiziologie
    Iași, 700115, Romania
  • Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea; Sectia Pneumologie I
    Oradea, 410176, Romania
  • Ryazan State Medical University Named after I.P.Pavlov
    Ryazan, Ryazan Oblast 390026, Russia
  • SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
    Saint Petersburg, Sankt-Peterburg 197022, Russia
  • St. Petersburg State Medical University n.a. I.P. Pavlov
    Saint Petersburg, Sankt-Peterburg 197089, Russia
  • City Hospital #40 of Resort Administrative District
    Saint Petersburg, Sankt-Peterburg 197706, Russia
  • LLC Medical Center "Alliance-Biomedical - Russian Group"
    Saint Petersburg, 190068, Russia
  • LLC Medical Center"REAVITA"
    Saint Petersburg, 194295, Russia
  • Multiple-discipline City Hospital #2
    Saint Petersburg, 194354, Russia
  • Regional Clinical Hospital
    Saratov, 410053, Russia
  • Ural State Medical University; Pulmonology
    Yekaterinburg, 620109, Russia
  • Tiervalei Trial Centre
    Cape Town, 7530, South Africa
  • University of Cape Town Lung Institute; Lung Clinical Research
    Cape Town, 7700, South Africa
  • Newtown Clinical Research
    Johannesburg, 2113, South Africa
  • I Engelbrecht Research
    Lyttleton, 0157, South Africa
  • Syzygy Clinical Research; ?Unit 3 to 7
    Pretoria Gauteng Province, 0087, South Africa
  • Soweto Clinical Trial Centre
    Soweto, 1818, South Africa
  • The Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Publications

  • Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13. PubMed 29413502 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jan 2016, 19 months.

Results were first posted in Jul 2026, 10 years 5 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 19 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2014
First posted
Apr 4, 2014
StartActual
Jun 7, 2014
Primary completionActual
Jan 22, 2016
CompletionActual
Jan 22, 2016
Results first posted
Jul 17, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02104674
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 4, 2014
Start date
Jun 7, 2014
Primary completion
Jan 22, 2016
Completion
Jan 22, 2016
Results posted
Jul 17, 2026
Last update
Jul 17, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion